1. European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP) Module VI – Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev.2). EMA. 2017. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf. Accessed 24 Jan 2022.
2. World Health Organization. Safety of medicines: priming resource-limited countries for pharmacovigilance. WHO Drug Inf. 2017;31(4):575–80.
3. The Global Fund, World Health Organization. Minimum requirements for a functional Pharmacovigilance system. WHO. 2010. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/PV_Minimum_Requirements_2010_2.pdf.
4. Accessed 24 Jan 2022.
5. CDER Office of Surveillance and Epidemiology. 2018 https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cder-office-surveillance-and-epidemiology. Accessed 21 Dec 2021.